Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity

To the editor: As more effective therapies become routinely used to treat multiple myeloma,[1][1] standardized methods (such as flow cytometry) to determine the presence/absence of minimal residual disease (MRD) will likely play an increasingly important role in the clinical, research, and